Evidence map›Paper›PMID 34053055›Full record

ReviewMethods in molecular biology (Clifton, N.J.)2021

A Review of Proteomics Strategies to Study T-Cell Activation and Function in Cancer Disease.

Massimo Papale

Abstract readReview
PubMed Publisher
In one paragraph

Review in Methods in molecular biology (Clifton, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Massimo PapaleClinical Pathology Unit, Department of Laboratory Diagnostics, Policlinic University Hospital "Riuniti", Foggia, Italy. massimo.papale@unifg.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytotoxic T-cells play a key role in natural response to cancer and in immunotherapy. Understanding in an ever more thorough and complete way the mechanisms underlying their activation and/or those that prevent it is a crucial challenge for the success of the therapy. Proteomics can make a decisive contribution to achieving this goal as it brings together a range of technologies that potentially allow the expression levels of thousands of proteins to be analyzed at the same time. In the first part of this chapter, after an overview of the main mechanisms that determine T-cell dysfunction, new MS-based approaches to characterizing T-cell subpopulations in the tumor microenvironment will be described. The second part of the chapter will focus on the main strategies for cancer immunotherapy, from the selective blockage of inhibitory receptor to CAR T therapy. Examples of proteomics application to tumor microenvironment analysis will be reported to illustrate how these innovative approaches can contribute significantly to understanding the cellular and molecular mechanisms that regulate an effective response to therapy.

Indexed as

Tumor MicroenvironmentAntigens, NeoplasmChromatography, LiquidHumansImmunotherapyImmunotherapy, AdoptiveLymphocyte ActivationMass SpectrometryNeoplasmsProteomicsReceptors, Chimeric AntigenSignal TransductionT-Lymphocytes, CytotoxicT-Lymphocyte SubsetsAntigens, NeoplasmReceptors, Chimeric AntigenCAR-TCytotoxic T-cellsImmunotherapyLC/MSMass CytometryProteomicsT-cell exhaustionTumor microenvironment (TME)

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.